7TM Pharma was developing obinepitide, a subcutaneously administered dual neuropeptide Y (NPY) Y2 and Y4 receptors agonist, for the treatment of obesity. Obinepitide is a synthetic analogue of two natural human hormones, PYY and Pancreatic Polypeptide, which normally are released during a meal. These hormones are known to play a role in the regulation of food intake and appetite in man as satiety signal from the GI-tract to the CNS. In obinepitide, the properties of both of these hormones have been implanted into a single molecule. Obinepitide targets the Y2 and Y4 receptors, with selectivity over the Y1 receptor, which is involved in causing cardiovascular side effects. Obinepitide inhibited food intake up to nine hours after dosing.

Pegorgotein (formerly known as PEG-SOD) was developed by Enzon pharmaceutical as a scavenger of oxygen-derived free radicals. This drug under the trade name DISMUTEC participated in phase III clinical trial in patients with a severe closed head injury. It was found that the drug failed to show a statistically significant difference between the treatment group and the control group. In spite of DISMUTEC exhibited longer circulating half-life and reduced immunogenicity; however, the drug showed insufficient therapeutic effect for this indication. In addition, pegorgotein was studied for patients with reperfusion injury and stroke. However, these studies were also discontinued.